Modelling the Cost Effectiveness of Rituximab in Chronic Lymphocytic Leukaemia in First-Line Therapy and Following Relapse

Rituximab, in combination with chemotherapy, when used multiple times throughout the treatment algorithm, appears to be cost effective for CLL from the Australian healthcare perspective, with a cost/QALYG within the range generally accepted as providing value. </AbstractSection> Copyright Springer International Publishing Switzerland 2014